These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 24024892)
1. Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report. Laurenty AP; Thomas F; Chatelut E; Bétrian S; Le Guellec C; Hennebelle I; Le Guellec S; Chevreau C Pharmacogenomics; 2013 Sep; 14(12):1389-96. PubMed ID: 24024892 [TBL] [Abstract][Full Text] [Related]
2. Trabectedin's contribution to the treatment of sarcomas. Blay JY Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729 [TBL] [Abstract][Full Text] [Related]
3. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558 [TBL] [Abstract][Full Text] [Related]
4. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Lee JK; Leslie EM; Zamek-Gliszczynski MJ; Brouwer KL Toxicol Appl Pharmacol; 2008 Apr; 228(1):17-23. PubMed ID: 18191164 [TBL] [Abstract][Full Text] [Related]
5. Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option. Schöffski P; Cerbone L; Wolter P; De Wever I; Samson I; Dumez H; Clement P; Wildiers H; Stas M Onkologie; 2012; 35(1-2):14-7. PubMed ID: 22310339 [TBL] [Abstract][Full Text] [Related]
6. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N; Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439 [TBL] [Abstract][Full Text] [Related]
8. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. Pick AM; Nystrom KK J Oncol Pharm Pract; 2010 Dec; 16(4):269-72. PubMed ID: 20015930 [TBL] [Abstract][Full Text] [Related]
9. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Amant F; Coosemans A; Renard V; Everaert E; Vergote I Int J Gynecol Cancer; 2009 Feb; 19(2):245-8. PubMed ID: 19396002 [TBL] [Abstract][Full Text] [Related]
11. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575 [No Abstract] [Full Text] [Related]
13. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Grosso F; Dileo P; Sanfilippo R; Stacchiotti S; Bertulli R; Piovesan C; Jimeno J; D'Incalci M; Gescher A; Casali PG Eur J Cancer; 2006 Jul; 42(10):1484-90. PubMed ID: 16737808 [TBL] [Abstract][Full Text] [Related]
14. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Daly AK; Aithal GP; Leathart JB; Swainsbury RA; Dang TS; Day CP Gastroenterology; 2007 Jan; 132(1):272-81. PubMed ID: 17241877 [TBL] [Abstract][Full Text] [Related]
15. Current questions in soft tissue sarcoma: further steps with Yondelis®. Reichardt P Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):25-30. PubMed ID: 23638728 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935 [TBL] [Abstract][Full Text] [Related]
17. Going further in the knowledge of Yondelis®; what's new in clinical trials? Blay JY Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046 [TBL] [Abstract][Full Text] [Related]
18. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes? Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE J BUON; 2010; 15(4):791-3. PubMed ID: 21229647 [TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Martin-Liberal J; Judson I Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190 [TBL] [Abstract][Full Text] [Related]
20. Trabectedin: Supportive care strategies and safety profile. Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]